{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T01:41:47Z","timestamp":1760060507498,"version":"build-2065373602"},"reference-count":34,"publisher":"MDPI AG","issue":"9","license":[{"start":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T00:00:00Z","timestamp":1756425600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Andr\u00e1s Gelley"},{"name":"Semmelweis University"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Antibiotics"],"abstract":"<jats:p>Background: The official current guideline for Helicobacter pylori (H. pylori) eradication is to use tetracycline\u2013bismuth-based protocols as first line treatment due to the increasing incidence of clarithromycin resistance in the last decade. The unavailability of tetracycline and bismuth-containing medicines, however, is an issue in many countries, limiting the routine use of these protocols. The value of using additional probiotics in eradication protocols is also unclear. Direct comparison data on the effect of available bismuth compounds and different probiotic strains on eradication outcome are limited. Goal: The aim of our investigation was to find optimal eradication protocols, supplementations and treatment duration for routine clinical use in our gastroenterology unit, located in a highly clarithromycin-resistant and tetracycline\u2013bismuth-na\u00efve area. Materials and Methods: We conducted a retrospective real-world data analysis of 402 H. pylori positive patients between 2016 and 2024. H. pylori infection was diagnosed using histological examination of gastroscopy samples obtained from the gastric antrum. For the evaluation of treatment success or failure, 14C breath tests and stool H. pylori antigen tests were performed. Data on patient characteristics and treatment protocols were collected from our electronic patient record system, and treatment success was compared between the different treatment regimes. Results: Despite the regional clarithromycin resistance, supplementing clarithromycin-based regimens with bismuth and probiotic during the 14-day treatment duration showed a high and comparable cure rate when compared to tetracycline-based regimens, which are the current first-line therapies. When tetracycline-based combination is available, it is recommended to use it with an additional probiotic to achieve the best possible outcome. Comparison of the effect of available bismuth preparations on treatment success showed no significant difference. Generally, probiotic-containing protocols are more successful, compared to those treatments without this supplement. There was no statistical difference in the cure rates amongst the four probiotic strains used, where sample size allowed statistical analysis. Furthermore, supplementation with probiotics Lactobacillus reuteri ATCC PTA 6475 or Lactobacillus reuteri Protectis\u00ae DSM 17938 showed promising high treatment success rates (85.2% and 100.0%, respectively) in our study.<\/jats:p>","DOI":"10.3390\/antibiotics14090870","type":"journal-article","created":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T16:42:21Z","timestamp":1756485741000},"page":"870","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optimizing the Routine Use of Clinical Guidelines by Addition of Supplements (Probiotics and\/or Bismuth) to Helicobacter pylori Eradication Protocols in a Clarithromycin Resistant and Tetracycline\/Bismuth Naive Area: A Real-World Data Retrospective Analysis of 402 Cases (2016\u201324) in a Single Gastroenterology Unit"],"prefix":"10.3390","volume":"14","author":[{"given":"Andr\u00e1s","family":"Gelley","sequence":"first","affiliation":[{"name":"Department of Internal Medicine, Gastroenterology and Endocrinology, Buda Hospital of the Hospitaller Order of Saint John of God, H-1027 Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"No\u00e9mi","family":"K\u00e9ri","sequence":"additional","affiliation":[{"name":"Department of Intensive Therapy, Faculty of Medicine, Semmelweis University, H-1085 Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"P\u00e9ter","family":"Birinyi","sequence":"additional","affiliation":[{"name":"Department of Pharmacodynamics, Faculty of Pharmacy, Semmelweis University, H-1085 Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kinga","family":"Komka","sequence":"additional","affiliation":[{"name":"Department of Chemical and Environmental Process Engineering, Faculty of Chemical Technology and Biotechnology, Budapest University of Technology and Economics, H-1111 Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vajk","family":"Hardy","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Gastroenterology and Endocrinology, Buda Hospital of the Hospitaller Order of Saint John of God, H-1027 Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"L\u00e1szl\u00f3","family":"D\u00f6ng\u00f6l\u0151","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Gastroenterology and Endocrinology, Buda Hospital of the Hospitaller Order of Saint John of God, H-1027 Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"D\u00f3ra","family":"Szeli","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, Gastroenterology and Endocrinology, Buda Hospital of the Hospitaller Order of Saint John of God, H-1027 Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ibolya","family":"Czegle","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine and Hematology, Faculty of Medicine, Semmelweis University, H-1085 Budapest, Hungary"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2025,8,29]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"1730","DOI":"10.14309\/ajg.0000000000002968","article-title":"ACG Clinical Guideline: Treatment of Helicobacter Pylori Infection","volume":"119","author":"Chey","year":"2024","journal-title":"Am. J. Gastroenterol."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1724","DOI":"10.1136\/gutjnl-2022-327745","article-title":"Management of Helicobacter Pylori Infection: The Maastricht VI\/Florence Consensus Report","volume":"71","author":"Malfertheiner","year":"2022","journal-title":"Gut"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"1461","DOI":"10.1556\/oh.2007.28013","article-title":"The Hungarian Epidemiology of Clarithromycin Resistance in Helicobacter Pylori Infection","volume":"148","author":"Lotz","year":"2007","journal-title":"Orv. Hetil."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"2255","DOI":"10.1038\/s41467-021-22557-7","article-title":"Primary and Secondary Clarithromycin Resistance in Helicobacter Pylori and Mathematical Modeling of the Role of Macrolides","volume":"12","author":"Szirtes","year":"2021","journal-title":"Nat. Commun."},{"key":"ref_5","doi-asserted-by":"crossref","unstructured":"Kouhsari, E., Sadeghifard, N., Khadiv, A., Sayadi, H., Amiriani, T., Ghafourian, S., Valadbeigi, H., and Krutova, M. (2022). Heteroresistance to Clarithromycin and Metronidazole in Patients with a Helicobacter Pylori Infection: A Systematic Review and Meta-Analysis. Ann. Clin. Microbiol. Antimicrob., 21.","DOI":"10.1186\/s12941-022-00509-3"},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"801","DOI":"10.3904\/kjim.2015.30.6.801","article-title":"Trends in Helicobacter Pylori Eradication Rates by First-Line Triple Therapy and Related Factors in Eradication Therapy","volume":"30","author":"Kim","year":"2015","journal-title":"Korean J. Intern. Med."},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"40","DOI":"10.1136\/gutjnl-2020-321372","article-title":"European Registry on Helicobacter Pylori Management (Hp-EuReg): Patterns and Trends in First-Line Empirical Eradication Prescription and Outcomes of 5 Years and 21533 Patients","volume":"70","author":"Nyssen","year":"2021","journal-title":"Gut"},{"key":"ref_8","doi-asserted-by":"crossref","unstructured":"Nyssen, O.P., Moreira, L., Garc\u00eda-Morales, N., Cano-Catal\u00e0, A., Puig, I., M\u00e9graud, F., O\u2019Morain, C., and Gisbert, J.P. (2022). European Registry on Helicobacter Pylori Management (Hp-EuReg): Most Relevant Results for Clinical Practice. Front. Gastroenterol., 1.","DOI":"10.3389\/fgstr.2022.965982"},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"1340","DOI":"10.1556\/650.2019.31477","article-title":"A Helicobacter pylori\u2014Fert\u0151z\u00e9s els\u0151 vonalbeli megsz\u00fcntet\u00e9s\u00e9re alkalmazott hagyom\u00e1nyos h\u00e1rmas \u00e9s egy \u00faj, bizmuttartalm\u00fa n\u00e9gyes kezel\u00e9s \u00f6sszehasonl\u00edt\u00e1sa","volume":"160","author":"Varga","year":"2019","journal-title":"Orv. Hetil."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1155\/2000\/690307","article-title":"Bismuth-Based Triple Therapy with Bismuth Subcitrate, Metronidazole and Tetracycline in the Eradication of Helicobacter Pylori: A Randomised, Placebo Controlled, Double-Blind Study","volume":"14","author":"Farley","year":"2000","journal-title":"Can. J. Gastroenterol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"2527539","DOI":"10.1080\/20565623.2025.2527539","article-title":"Comparison of Bismuth and Concomitant Therapy for H. Pylori Eradication: A Prospective, Randomized Clinical Trial","volume":"11","author":"Oueslati","year":"2025","journal-title":"Future Sci. OA"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"e751","DOI":"10.1097\/MJT.0000000000000389","article-title":"Role of Bismuth in the Eradication of Helicobacter Pylori","volume":"24","author":"Alkim","year":"2017","journal-title":"Am. J. Ther."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"97","DOI":"10.13105\/wjma.v3.i2.97","article-title":"Meta-Analysis of Single Strain Probiotics for the Eradication of Helicobacter Pyloriand Prevention of Adverse Events","volume":"3","author":"McFarland","year":"2015","journal-title":"World J. Meta-Anal."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"03000605231203841","DOI":"10.1177\/03000605231203841","article-title":"Efficacy and Safety of Probiotic-Supplemented Bismuth Quadruple Therapy for the Treatment of Helicobacter Pylori Infection: A Systematic Review and Meta-Analysis","volume":"51","author":"Yao","year":"2023","journal-title":"J. Int. Med. Res."},{"key":"ref_15","doi-asserted-by":"crossref","unstructured":"Buz\u00e1s, G.M., and Birinyi, P. (2023). Newer, Older, and Alternative Agents for the Eradication of Helicobacter Pylori Infection: A Narrative Review. Antibiotics, 12.","DOI":"10.3390\/antibiotics12060946"},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Li, M., and Xie, Y. (2025). Efficacy and Safety of Saccharomyces Boulardii as an Adjuvant Therapy for the Eradication of Helicobacter Pylori: A Meta-Analysis. Front. Cell. Infect. Microbiol., 15.","DOI":"10.3389\/fcimb.2025.1441185"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"e13017","DOI":"10.1111\/hel.13017","article-title":"Probiotic Containing Lactobacillus Reuteri DSM 17648 as an Adjunct Treatment for Helicobacter Pylori Infection: A Randomized, Double-blind, Placebo-controlled Trial","volume":"28","author":"Ismail","year":"2023","journal-title":"Helicobacter"},{"key":"ref_18","doi-asserted-by":"crossref","unstructured":"Naghibzadeh, N., Salmani, F., Nomiri, S., and Tavakoli, T. (2022). Investigating the Effect of Quadruple Therapy with Saccharomyces Boulardii or Lactobacillus Reuteri Strain (DSMZ 17648) Supplements on Eradication of Helicobacter Pylori and Treatments Adverse Effects: A Double-Blind Placebo-Controlled Randomized Clinical Trial. BMC Gastroenterol., 22.","DOI":"10.1186\/s12876-022-02187-z"},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1002\/jgh3.12208","article-title":"Real-world Data of Helicobacter Pylori Prevalence, Eradication Regimens, and Antibiotic Resistance in Thailand, 2013\u20132018","volume":"4","author":"Shoosanglertwijit","year":"2020","journal-title":"JGH Open"},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"4846","DOI":"10.3748\/wjg.v26.i32.4846","article-title":"Current Status of Helicobacter Pylori Eradication and Risk Factors for Eradication Failure","volume":"26","author":"Yan","year":"2020","journal-title":"World J. Gastroenterol."},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"601","DOI":"10.1016\/j.jmii.2024.02.009","article-title":"The Multicenter Real-World Report of the Efficacies of 14-Day Esomeprazole-Based and Rabeprazole-Based High-Dose Dual Therapy in First-Line Helicobacter Pylori Eradication in Taiwan","volume":"57","author":"Tai","year":"2024","journal-title":"J. Microbiol. Immunol. Infect."},{"key":"ref_22","doi-asserted-by":"crossref","unstructured":"Salmanroghani, H., Mirvakili, M., Baghbanian, M., Salmanroghani, R., Sanati, G., and Yazdian, P. (2018). Efficacy and Tolerability of Two Quadruple Regimens: Bismuth, Omeprazole, Metronidazole with Amoxicillin or Tetracycline as First-Line Treatment for Eradication of Helicobacter Pylori in Patients with Duodenal Ulcer: A Randomized Clinical Trial. PLoS ONE, 13.","DOI":"10.1371\/journal.pone.0197096"},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1007\/s10620-021-07323-5","article-title":"Pitfalls of Physician-Directed Treatment of Helicobacter Pylori: Results from Two Phase 3 Clinical Trials and Real-World Prescribing Data","volume":"67","author":"Howden","year":"2022","journal-title":"Dig. Dis. Sci."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.3748\/wjg.v30.i39.4295","article-title":"Efficacy and Safety of Low-Dose Tetracycline, Amoxicillin Quadruple Therapy in Helicobacter Pylori Infection: A Retrospective Single Center Study","volume":"30","author":"Zhao","year":"2024","journal-title":"World J. Gastroenterol."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"397","DOI":"10.1155\/2013\/801915","article-title":"Prolonged Treatment Duration Is Required for Successful Helicobacter Pylori Eradication with Proton Pump Inhibitor Triple Therapy in Canada","volume":"27","author":"Fallone","year":"2013","journal-title":"Can. J. Gastroenterol."},{"key":"ref_26","doi-asserted-by":"crossref","unstructured":"Hu, J., Tian, X., Wei, T., Wu, H., Lu, J., Lyu, M., and Wang, S. (2021). Anti-Helicobacter pylori Activity of a Lactobacillus sp. PW-7 Exopolysaccharide. Foods, 10.","DOI":"10.3390\/foods10102453"},{"key":"ref_27","doi-asserted-by":"crossref","unstructured":"Alam, K., Hao, J., Zhang, Y., and Li, A. (2021). Synthetic biology-inspired strategiesand tools for engineering of microbial natural product biosynthetic pathways. Biotechnol Adv., 49.","DOI":"10.1016\/j.biotechadv.2021.107759"},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2300241","DOI":"10.1002\/mnfr.202300241","article-title":"Lactiplantibacillus plantarum ZJ316 Reduces Helicobacter pylori Adhesion and Inflammation by Inhibiting the Expression of Adhesin and Urease Genes","volume":"67","author":"Wu","year":"2023","journal-title":"Mol. Nutr. Food Res."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"458","DOI":"10.1016\/j.jbiosc.2018.04.003","article-title":"Antagonistics of Lactobacillus plantarum ZDY2013 against Helicobacter pylori SS1 and its infection in vitro in human gastric epithelial AGS cells","volume":"126","author":"Zhao","year":"2018","journal-title":"J. Biosci. Bioeng."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"6510","DOI":"10.1021\/acs.jafc.1c01070","article-title":"Lactobacillus plantarum ZJ316 attenuates Helicobacter pylori -induced gastritis in C57BL\/6 mice","volume":"69","author":"Zhou","year":"2021","journal-title":"J. Agric. Food Chem."},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"2108655","DOI":"10.1080\/19490976.2022.2108655","article-title":"The double-edged sword of probiotic supplementation on gut microbiota structure in Helicobacter pylori management","volume":"14","author":"Sadeghi","year":"2022","journal-title":"Gut Microbes"},{"key":"ref_32","doi-asserted-by":"crossref","unstructured":"Xu, W., Xu, L., and Xu, C. (2022). Relationship between Helicobacter pylori infection and gastrointestinal microecology. Front. Cell. Infect. Microbiol., 12.","DOI":"10.3389\/fcimb.2022.938608"},{"key":"ref_33","unstructured":"Watson, R.R., and Preedy, V.R. (2016). Amelioration of Helicobacter pylori-induced PUD by probiotic lactic acid bacteria. Probiotics, Prebiotics and Synbiotics, Academic Press-Elsevier."},{"key":"ref_34","doi-asserted-by":"crossref","unstructured":"Yuan, L., Yang, C., Han, Y., Yang, F., and Tu, H. (2025). Beyond antibiotics: Probiotics as a promising ally against Helicobacter pylori. Front. Pharmacol., 16.","DOI":"10.3389\/fphar.2025.1620870"}],"container-title":["Antibiotics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/9\/870\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,9]],"date-time":"2025-10-09T18:35:13Z","timestamp":1760034913000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2079-6382\/14\/9\/870"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8,29]]},"references-count":34,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2025,9]]}},"alternative-id":["antibiotics14090870"],"URL":"https:\/\/doi.org\/10.3390\/antibiotics14090870","relation":{},"ISSN":["2079-6382"],"issn-type":[{"type":"electronic","value":"2079-6382"}],"subject":[],"published":{"date-parts":[[2025,8,29]]}}}